Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. It also develops next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALRN
CUSIPN/A
Phone617-995-0900
Debt
Debt-to-Equity RatioN/A
Current Ratio9.16
Quick Ratio9.16
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.25 per share
Price / Book1.85
Profitability
EPS (Most Recent Fiscal Year)($1.77)
Net Income$-22,600,000.00
Net MarginsN/A
Return on Equity-461.02%
Return on Assets-58.75%
Miscellaneous
Employees13
Outstanding Shares14,740,000
Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions
What is Aileron Therapeutics' stock symbol?
Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."
How were Aileron Therapeutics' earnings last quarter?
Aileron Therapeutics Inc (NASDAQ:ALRN) posted its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.02. View Aileron Therapeutics' Earnings History.
What price target have analysts set for ALRN?
4 brokers have issued twelve-month target prices for Aileron Therapeutics' stock. Their forecasts range from $19.00 to $20.00. On average, they expect Aileron Therapeutics' stock price to reach $19.3333 in the next year. View Analyst Ratings for Aileron Therapeutics.
Who are some of Aileron Therapeutics' key competitors?
Some companies that are related to Aileron Therapeutics include BioSpecifics Technologies (BSTC), Strongbridge Biopharma (SBBP), Ra Pharmaceuticals (RARX), resTORbio (TORC), Axovant Sciences (AXON), Galectin Therapeutics Inc. Common Stock (GALT), Ocular Therapeutix (OCUL), Kadmon (KDMN), Kindred Biosciences (KIN), Biofrontera (BFRA), CTI BioPharma (CTIC), Selecta Biosciences (SELB), ASLAN PHARMACEUTICALS ADR REP 5 (ASLN), AVEO Pharmaceuticals (AVEO) and Marinus Pharmaceuticals (MRNS).
Who are Aileron Therapeutics' key executives?
Aileron Therapeutics' management team includes the folowing people:
- Mr. Joseph A. Yanchik III, Founder, Pres, CEO & Director (Age 54)
- Dr. Manuel C. Aivado, Sr. VP, Chief Medical Officer & Chief Scientific Officer (Age 48)
- Mr. Huw M. Nash Ph.D., Co-Founder
- Mr. Donald V. Dougherty CPA, CFA, Sr. VP & CFO (Age 59)
- Ms. Kira A. Nelson CPA, VP of Fin. & Operations (Age 49)
When did Aileron Therapeutics IPO?
(ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.
Has Aileron Therapeutics been receiving favorable news coverage?
News stories about ALRN stock have trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aileron Therapeutics earned a daily sentiment score of 0.18 on Accern's scale. They also assigned press coverage about the company an impact score of 46.37 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are Aileron Therapeutics' major shareholders?
Aileron Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.13%). Company insiders that own Aileron Therapeutics stock include Apple Tree Partners Ii Lp, Cvf, Llc, Donald Dougherty, Lilly Ventures Fund I Llc, Manuel Aivado and Reinhard J Ambros. View Institutional Ownership Trends for Aileron Therapeutics.
Which institutional investors are buying Aileron Therapeutics stock?
ALRN stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC. Company insiders that have bought Aileron Therapeutics stock in the last two years include Cvf, Llc, Donald Dougherty, Lilly Ventures Fund I Llc, Manuel Aivado and Reinhard J Ambros. View Insider Buying and Selling for Aileron Therapeutics.
How do I buy shares of Aileron Therapeutics?
Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aileron Therapeutics' stock price today?
One share of ALRN stock can currently be purchased for approximately $6.02.
How big of a company is Aileron Therapeutics?
Aileron Therapeutics has a market capitalization of $77.81 million. The company earns $-22,600,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Aileron Therapeutics employs 13 workers across the globe.
How can I contact Aileron Therapeutics?
Aileron Therapeutics' mailing address is 281 ALBANY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-995-0900 or via email at [email protected]
MarketBeat Community Rating for Aileron Therapeutics (ALRN)
MarketBeat's community ratings are surveys of what our community members think about Aileron Therapeutics and other stocks. Vote "Outperform" if you believe ALRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
